Sorrento to file IND for anti-SARS-CoV-2 nasal drops

By The Science Advisory Board staff writers

November 11, 2020 -- Sorrento Therapeutics is filing an investigational new drug application (IND) with the U.S. Food and Drug Administration for its STI-2099 (Covi-Drops), an intranasal formula of a neutralizing antibody against SARS-CoV-2.

Sorrento will study the safety and pharmacokinetics of Covi-Drops in healthy volunteers and patients with mild COVID-19 in a phase I trial if the agency authorizes the IND.

The drops demonstrated a 100% neutralizing effect in vitro and in vivo. At very low doses, they prevented SARS-CoV-2 from infecting healthy cells and causing COVID-19-like disease in Syrian golden hamsters, according to preclinical data.

Sorrento plans phase II trial for COVID-19 treatment
Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment...
Sorrento moves forward with COVID-19 prophylactic drug
Sorrento has completed preclinical testing of STI-4398 (COVIDTRAP), reporting positive results on the protein's ability to neutralize and inhibit the...
Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.

Copyright © 2020

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter